Cargando…
Dapagliflozin for the treatment of type 2 diabetes: a review of the literature
OBJECTIVE: Dapagliflozin was the first drug in a class of therapies that took a new approach to glycemic control in adults with type 2 diabetes (T2D). It is an inhibitor of the sodium glucose cotransporter, resident in the proximal nephron, which is responsible for the recovery of filtered glucose b...
Autores principales: | Saeed, Mujahid A, Narendran, Parth |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4267514/ https://www.ncbi.nlm.nih.gov/pubmed/25525338 http://dx.doi.org/10.2147/DDDT.S50963 |
Ejemplares similares
-
Dapagliflozin: an evidence-based review of its potential in the treatment of type-2 diabetes
por: Chao, Edward C
Publicado: (2012) -
Dapagliflozin: A Review in Type 2 Diabetes
por: Dhillon, Sohita
Publicado: (2019) -
Correction to: Dapagliflozin: A Review in Type 2 Diabetes
por: Dhillon, Sohita
Publicado: (2019) -
Dapagliflozin: A Review in Type 1 Diabetes
por: Paik, Julia, et al.
Publicado: (2019) -
Differential pharmacology and clinical utility of dapagliflozin in type 2 diabetes
por: Papakitsou, Ioanna, et al.
Publicado: (2019)